Every letter we have printed

Units are quietly inconsistent across this trade. Water content by weight and water content by the Karl Fischer determination are usually the same thing and occasionally are not, and the abbreviation on the page does not distinguish them.

Delayed gastric emptying explains a good part of the early symptoms and it is also part of the intended effect, which makes the framing of these as unwanted effects slightly awkward. Your piece handles the tension well rather than pretending it is not there.

Meal composition interacts with the mechanism in ways the literature has measured and popular coverage never mentions. Fat content in particular changes emptying substantially at baseline, before anything else is introduced.

Baseline variation in transit time across a healthy population is wide enough to swamp small effects, and studies with modest sample sizes are therefore measuring a difference against a very noisy background. Confidence intervals in this literature are wide for good reasons.

Tachyphylaxis in the emptying effect is well described and rarely mentioned outside the specialist literature. A mechanism that attenuates over weeks explains a great deal of the time course that otherwise looks mysterious.

What proportion of participants reached the target dose is a single number reported in most of these papers and quoted in almost none. It is the most direct statement of tolerability the study contains.

Residual gastric content is measurable and has been measured in small studies with results that do not entirely agree. Coverage tends to quote whichever study supports the position being argued, and the disagreement itself is the finding.

Trial populations were selected, monitored and supported in ways that the general population is not, and event reporting in a trial is systematic in a way that reporting outside one never is. Both facts push the comparison in opposite directions and neither is usually mentioned.

A quiet objection to the whole framing. Blind purchasing treats suppliers as adversaries, which is a reasonable design assumption and a poor description of most of the trade. The programmes that have learned most have been the ones willing to ask questions as well as run tests.

A properly blind purchase means buying as an ordinary customer, from the ordinary catalogue, with no indication that the vial is going anywhere but a domestic address. Anything less and the supplier has had an opportunity, however small, to treat that order differently.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

An image is a poor container for a conditional statement. Everything interesting about a determination is conditional — on the sample, the method, the date — and none of it survives compression into a graphic. The format has selected the message.

The test is destructive, which is the point your piece makes lightly and which deserves more weight. Every unit tested is a unit that cannot be sold, and on a small fill that is a real proportion of the batch. It is an argument for process assurance rather than for testing more.

I priced a sterility and endotoxin package for a small batch last year and the cost per surviving vial was substantial but not prohibitive. The obstacle was not money. It was that no supplier I approached had a route to commission it, and none of them had ever been asked.

The most useful thing a supplier can publish is its packing specification: pack type, quantity, insulation, and the tested hold time at a stated ambient. It is a page of text and it would let a buyer reason about their own climate.

The customs hold is the invisible leg. A parcel detained for four days has a thermal history nobody records, and the only trace of it is a gap in the tracking that most buyers never look at.

Stopper choice belongs in this section. A stopper that has not been properly dried will release water into the headspace over months, and a cake that left the plant at one per cent moisture will not still be at one per cent when it arrives. The container is part of the formulation.

The comparison your readers want is between an excursion and the stability data that would justify tolerating it. Without accelerated stability figures for the specific formulation, an excursion assessment is judgement dressed as calculation. Very few suppliers in this trade hold those figures.

Your worked example is correct and I would extend it. A 5 mg vial reconstituted with 2 mL gives 2.5 mg per mL, so 0.2 mL contains 0.5 mg and reads as 20 units on a hundred-unit barrel. Every step of that is division and every step of it gets skipped.

Displacement is small for these quantities and not always negligible. Adding 2 mL of diluent to a vial containing a few milligrams of solid gives very slightly more than 2 mL of solution. It is a fraction of a per cent and it is worth knowing that the direction of the error is always the same.

On the denominator: I have seen certificates where the counter-ion peak was excluded and certificates where it was not, and the difference on a trifluoroacetate salt is not small. Neither certificate said which had been done. A single line stating what was excluded from the total area would settle it.

Manual reintegration deserves a harder look than the article gives it. Every chromatography data system logs it, the audit trail is right there, and in a regulated environment it would be reviewed. Outside one, nobody ever asks for the trail, and the setting that most affects the answer is the one with the least scrutiny.

Your table of what each method can see puts "only if resolved" against isoaspartate for RP-HPLC. That understates the difficulty. Resolving isoAsp from Asp routinely requires a method developed for the purpose, and on a generic gradient the two are frequently indistinguishable even at forty minutes.

The cheapest orthogonal method is not a second column, it is a change of mobile-phase pH on the column already installed. Formic acid in place of trifluoroacetic acid alters selectivity substantially for basic sequences and costs one equilibration. It is not a full second principle, and it will still separate a co-eluting pair more often than not.

Intervals are periodically revised, and a laboratory that changes its interval will produce an apparent change in a patient whose biology did not move. The revision date is on the report and nobody reads it.

Biological variation within one person is smaller than the variation between people for many analytes, which is why a series of results on one individual is far more informative than a single result against a population interval.

Gallbladder-related findings follow rapid weight loss from any cause and are not specific to any pharmacology. Attributing them to the agent rather than to the rate of loss is a common error and the distinction matters for what somebody does next. This is not medical advice.

The most useful presentation of a series is a plot with the interval as a shaded band. Every laboratory has the data to produce it and almost none do, and readers are left comparing rows of numbers by eye.

Repeated puncture of a stopper is a sterility question and a stability one. Each entry admits a small volume of air, and oxidation-sensitive residues care about that whether or not anything grows.

The diluent is the variable nobody records. Bacteriostatic and plain water produce solutions with different chemistry and different in-use expectations, and accounts of stability in this market rarely state which was used.

Retest date and expiry date are different concepts and the trade uses them interchangeably. A retest date says the material may be re-examined and used if it still conforms; an expiry says it may not. Printing one and meaning the other is a small dishonesty that has become a convention.

The mean kinetic temperature explanation is the clearest I have read anywhere, including in the training my employer paid for. I have printed the sidebar and put it on the wall of the dispatch room.

Injecting into an area about to be exercised heavily raises local blood flow and can alter absorption. It is a small effect for weekly molecules and worth a sentence for completeness.

Recording the site alongside the date turns a habit into data, and anybody keeping such a record for six months will learn more about their own pattern than any general advice can tell them.

The hundred-unit convention is the source of more confusion than anything else in this subject, because the graduation is a volume marking that was designed for a different drug at a fixed concentration. On a syringe marked to a hundred units, one unit is a hundredth of a millilitre and nothing else. Everything downstream follows from that single sentence.

As a practice nurse I would add the ten-second hold to your list of things people skip. I watch patients withdraw immediately and then wonder about the wet patch on their skin. It is the most visible underdose there is and almost nobody connects the two.

Retitration after an interruption is discussed as though the tolerance acquired during the first course persists. Whether it does is an empirical question and I can find no study addressing it in this class.

Re-titration after an interruption is the question I am asked most often and the one with the least published guidance. The pharmacokinetic reasoning is straightforward: after several half-lives the exposure has gone, and resuming at the previous dose is resuming without the accommodation that produced tolerance.

Where the material is of uncertain content, an apparent plateau may be a supply event rather than a physiological one. That possibility exists in this market and in no clinical trial, and it deserves to be named in any coverage aimed at these readers.

Stepping back down a dose is treated in most discussion as a failure and it is a normal manoeuvre. Where a step up was poorly tolerated, returning to the previous dose and staying there longer is exactly what a tolerability-led approach implies. Nothing here is medical advice and the decision belongs with a clinician.